CPhl China 2023 Invitation

2023/04/20

Related News

Beilu Pharmaceutical Jiuwei Zhenxin granule was selected into the
November 30, 2021Recently, Beilu Pharmaceutical Jiuwei Zhenxin Granules were successfully selected into the "Science and Innovation China" New Drug Achievement Case Library of the China Association for Scien...view
Beijing Beilu Pharmaceutical Invites You to Participate in the 2023 Beijing International LIfe and Health Industry Expo
May 29, 2023Beijing Beilu Pharmaceutical Co., Ltd invites youto participate in the 2023 World Life Science Conference and Beijing International Life and Health Industry Cross-border ExpoBooth Number: 1B210Exhibit...view
Beilu was awarded the “Top 100 Small and Medium-sized Private Enterprises in Beijing” and “Top 100 Private Enterprises in Beijing for Social Responsibility”
September 17, 2021Recently, the Beijing Municipal Federation of Industry and Commerce and the Beijing Branch of China Construction Bank jointly held the“2021 Beijing Top 100 Private Enterprises Press Conference”.view
Adverse Reaction and Treatment of Contrast Medium
December 3, 2020Adverse drug reactions refer to harmful reactions that have nothing to do with the purpose of medication or accidentally occur under normal usage and dosage of qualified drugs.view
Frequently Asked Questions about Iodine Contrast Users (3)
May 13, 20211. Does the iodinated contrast agent need to be preheated? Can the patient benefit from it?Preheating the iodinated contrast agent before use is recognized as the best method of application.view
Iohexol from Beilu Pharma's holding subsidiary Zhejiang Hichi Pharmaceutical Corporation Limited has been registered with CDSCO
March 7, 2023Recently, Zhejiang Haichang Pharmaceutical Co., Ltd., a subsidiary of Beijing Beilu Pharmaceutical Co., Ltd., received a registration certificate for its active pharmaceutical ingredient product from ...view

CPhl China 2023 Invitation

Beilu Pharmaceutical Jiuwei Zhenxin granule was selected into the

Beijing Beilu Pharmaceutical Invites You to Participate in the 2023 Beijing International LIfe and Health Industry Expo

Beilu was awarded the “Top 100 Small and Medium-sized Private Enterprises in Beijing” and “Top 100 Private Enterprises in Beijing for Social Responsibility”

Adverse Reaction and Treatment of Contrast Medium

Frequently Asked Questions about Iodine Contrast Users (3)

Iohexol from Beilu Pharma's holding subsidiary Zhejiang Hichi Pharmaceutical Corporation Limited has been registered with CDSCO